Trials / Unknown
UnknownNCT05137522
Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH
Chidamide Combines With Etoposide and Methylprednisolone in the Treatment of Hemophagocytic Lymphohistiocytosis
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Beijing Friendship Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Chidamide combines with VP-16 and methylprednisolone in HLH
Detailed description
This study aimed to investigate the efficacy and safety of Chidamide together with Etoposide and methylprednisolone for hemophagocytic lymphohistiocytosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chidamide combines with VP-16 and methylprednisolone | Chidamide 30mg TIW po，etoposide 100 mg/m2 was administered day1; methylprednisolone 2mg/kg days 1 to 3,then 0.75mg/kg day 4 to 6，0.25mg/kg day 7 to 9，and 0.1mg/kg day 10 to 21 |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2023-07-01
- Completion
- 2023-07-01
- First posted
- 2021-11-30
- Last updated
- 2021-11-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05137522. Inclusion in this directory is not an endorsement.